Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis

This study has been completed.
Information provided by (Responsible Party):
Shire Identifier:
First received: April 15, 2009
Last updated: April 25, 2014
Last verified: April 2014
The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis

Condition Intervention Phase
Allergic Conjunctivitis
Drug: Lifitegrast
Other: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 2, Single Center, Randomized, Double-Masked and Placebo Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1, 1.0, 5.0%) of SAR 1118 Ophthalmic Solution in a Modified Conjunctival Allergen Challenge (CAC) Model

Resource links provided by NLM:

Further study details as provided by Shire:

Primary Outcome Measures:
  • Ocular itching and conjunctival redness at defined timepoints. [ Time Frame: Visit 4 and 6 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety and tolerability in subjects with allergic conjunctivitis. [ Time Frame: Visit 3, 4, 5 and 6 ] [ Designated as safety issue: No ]

Enrollment: 60
Study Start Date: April 2009
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 0.1% Lifitegrast Drug: Lifitegrast
Ophthalmic Solution
Other Name: SAR 1118
Experimental: 1.0% Lifitegrast Drug: Lifitegrast
Ophthalmic Solution
Other Name: SAR 1118
Experimental: 5.0% Lifitegrast Drug: Lifitegrast
Ophthalmic Solution
Other Name: SAR 1118
Placebo Comparator: Placebo Other: Placebo
Ophthalmic Solution


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent form and HIPAA document
  • Willing and able to comply with all study procedures
  • Be at least 18 years of age at the time of enrollment
  • 20/40 vision, or better, in each eye
  • History of ocular allergies, and a positive skin and ocular allergic reaction to allergens
  • A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period

Exclusion Criteria:

  • Preauricular lymphadenopathy or any ocular condition that could affect study parameters (particularly, glaucoma, diabetic retinopathy, clinically significant blepharitis, follicular conjunctivitis and iritis)
  • Have had any ocular infection within the last 30 days
  • A positive diagnosis of moderate to severe dry eye syndrome (i.e., requiring daily use of artificial tears)
  • Any significant illness that could be expected to interfere with study parameters
  • Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye
  • Use of any investigational product or device within one month prior to Visit 1 or during the study period
  • Concomitant use of any prohibited medication (antihistamines, corticosteroids, all ocular medications or anti-allergic therapies) during the trial or within the washout period
  • Any blood donation or significant loss of blood within 56 days of Visit 1
  • Any history of autoimmune disease, immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti‑HAV IgM), or organ or bone marrow transplant. Any known history of iritis/uveitis, glaucoma, or other chronic ophthalmologic disorder other than allergic conjunctivitis
  • History of laser‑assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 3 months prior to Visit 1
  • Known history of alcohol abuse and/or drug abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00882687

United States, Massachusetts
Andover, Massachusetts, United States, 01810
Sponsors and Collaborators
Principal Investigator: Gail Torkildsen, MD ORA, Inc.
  More Information

Responsible Party: Shire Identifier: NCT00882687     History of Changes
Other Study ID Numbers: 1118-ACJ-100 
Study First Received: April 15, 2009
Last Updated: April 25, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Immune System Diseases
Ophthalmic Solutions
Pharmaceutical Solutions processed this record on January 18, 2017